1188266-14-9

Yellow Solid

Labeled Nifedipine, intended for use as an internal standard for the quantification of Nifedipine by GC- or LC-mass spectrometry.

Used as an antihypertensive and antianginal. A labelled dihydorpyridine calcium channel blocker

Nifedipine-d₆ is intended for use as an internal standard for the quantification of nifedipine by GC- or LC-MS. Nifedipine is a dihydropyridine L-type calcium channel blocker that reduces the amplitude of spontaneous contractions in isolated rabbit ileum when used at a concentration of 1 μM. Nifedipine (1 μM) reduces TGF-β-induced calcium oscillations in human fibroblasts and prevents impairment of lung function in a mouse model of pulmonary fibrosis induced by bleomycin when administered at a dose of 10 mg/kg per day. It also reduces increases in mean arterial blood pressure induced by angiotensin II in spontaneously hypertensive rats when administered at a dose of 10 μg/kg. Formulations containing nifedipine have been used in the treatment of hypertension and angina.

[1] MERHAN RAGY  Eman E. The role of nitric oxide and L-type calcium channel blocker in the contractility of rabbit ileum in vitro.[J]. Journal of physiology and biochemistry, 2012: 521-528. DOI: 10.1007/s13105-012-0167-x
[2] SUBHENDU MUKHERJEE. Disruption of Calcium Signaling in Fibroblasts and Attenuation of Bleomycin-Induced Fibrosis by Nifedipine.[J]. American Journal of Respiratory Cell and Molecular Biology, 2015, 53 4: 450-458. DOI: 10.1165/rcmb.2015-0009oc
[3] SHIZUKA ARITOMI  Michihiro Y  Tomoyuki Konda. L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.[J]. Heart and Vessels, 2012, 27 4: 419-423. DOI: 10.1007/s00380-011-0191-8